HER2+ status is associated with aggressive disease1
HER2 positivity is correlated with decreased survival1
These patients did not receive HER2-directed therapy.
Breast carcinoma tissue from primary breast cancer biopsies was obtained from 220 randomly selected patients treated at the Glasgow Royal Infirmary between 1984 and 1993, 50 of whom were HER2-positive (HER2+).*
HER2 was localized using the ICR12 antibody. Survival curve includes patients with strongly stained tumors (IHC 3+/HER2+; n=50) vs HER2– or weakly stained (IHC 0 or 1+; n=85) tumors; 85 tumors in the study were considered moderately stained. †P value represents log-rank difference in cumulative survival.
Patients with breast tumors that over-express HER2 have shorter time to relapse and reduced overall survival2-6
HER2 positivity is a negative prognostic factor that should be considered even in patients conventionally considered low risk for disease recurrence1,7
- Patients with HER2+ disease with small tumors8
- Patients with HER2+ and hormone receptor + disease9